Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOLASE, INCBIOL · Entity 11470 | Director | June 30, 2017 | July 03, 2017 |
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | September 10, 2003 | September 12, 2003 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director | January 19, 2021 | February 05, 2021 |
| Lux Health Tech Acquisition Corp.LUXA · Entity 145615 | Director | October 26, 2020 | October 26, 2020 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director | June 09, 2026 | June 10, 2026 |
| SS Innovations International, Inc.SSII · Entity 5246 | Director · 10% owner | March 06, 2026 | March 10, 2026 |
| Venus Concept Inc.VERO · Entity 55304 | Director | November 07, 2019 | November 08, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOLASE, INC
Report date June 30, 2017 · Filed July 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,317 |
Reported balance
After 2017-06-30 transaction · row 1
1 source rowRow 1 · 2017-06-30 · Conversion · Acquired 192,100 · Balance 251,317 F1: On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.24 per share. |
| Series D Participating Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.24 | Direct | 0 |
Reported balance
After 2017-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-30 · Conversion · Disposed 1,921 · Balance 0 F2: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by Frederic H. Moll in a private placement with the Issuer, which closed on April 18, 2017. F3: The Preferred Stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 30, 2017, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.24 per share.
F2: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") were acquired by Frederic H. Moll in a private placement with the Issuer, which closed on April 18, 2017.
F3: The Preferred Stock had no expiration date.
INTUITIVE SURGICAL INC
Report date September 10, 2003 · Filed September 12, 2003
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 657,799 |
Ending reported balance
After 2003-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2003-09-10 · Sale · Disposed 5,000 · Balance 662,799 Row 2 · 2003-09-10 · Sale · Disposed 5,000 · Balance 657,799 |
Intersect ENT, Inc.
Report date January 19, 2021 · Filed February 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 260,961 |
Reported balance
After 2021-01-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-01-19 · Exercise / conversion · Acquired 12,500 · Balance 260,961 F1: Includes 5,011 restricted stock units. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.72 · Expires 2021-01-31 | Direct | 0 |
Reported balance
After 2021-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-19 · Exercise / conversion · Disposed 12,500 · Balance 0 F2: The vesting commencement date of the option is February 1, 2011. 7500 shares subject to the option vested on February 2, 2011 and 1/60th of the shares subject to the option vested monthly thereafter over 24 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 5,011 restricted stock units.
F2: The vesting commencement date of the option is February 1, 2011. 7500 shares subject to the option vested on February 2, 2011 and 1/60th of the shares subject to the option vested monthly thereafter over 24 months.
Lux Health Tech Acquisition Corp.
Report date October 26, 2020 · Filed October 26, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-26 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B common stock will automatically convert into shares of Class A common stock at the completion of the Issuer's initial business combination on a one-for-one basis, subject to adjustment. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B common stock will automatically convert into shares of Class A common stock at the completion of the Issuer's initial business combination on a one-for-one basis, subject to adjustment.
PROCEPT BioRobotics Corp
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 866,474 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 3,315 · Balance 866,474 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.78 · Expires 2036-06-08 | Direct | 5,853 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 5,853 · Balance 5,853 F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The securities shall vest in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
F2: The Stock option was granted on June 9, 2026, and vests in full on the earlier to occur of (i) the one-year anniversary of the grant date, or (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
SS Innovations International, Inc.
Report date March 06, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 10,775,485 |
Reported balance
After 2026-03-06 transaction · row 1
1 source rowRow 1 · 2026-03-06 · Purchase · Acquired 501,253 · Balance 10,775,485 |
Venus Concept Inc.
Report date November 07, 2019 · Filed November 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 207,381 |
Reported balance
After 2019-11-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-11-07 · Grant · Acquired 145,394 · Balance 207,381 F1: Received in connection with the Merger, upon the conversion of the outstanidng principal and any accrued and unpaid interest of two 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of August 14, 2019 and August 21, 2019, in the original principal amounts of $197,142.85 and $802,857.15, respectively. F2: Dr. Moll's previously reported holdings of common stock of the Issuer of 929,809 shares was adjusted to reflect the Issuer's 1-for-15 reverse stock split that occurred on November 7, 2019, which resulted in Dr. Moll's ownership of 867,822 less shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 659,788 |
Reported balance
After 2019-11-07 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2019-11-07 · Conversion · Acquired 452,407 · Balance 659,788 F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. |
| Common StockSEC Table I · non-derivative | Direct | 950,553 |
Reported balance
After 2019-11-07 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2019-11-07 · Conversion · Acquired 290,765 · Balance 950,553 F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. |
| Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28 | Direct | 0 |
Reported balance
After 2019-11-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0 F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. F6: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $3,165,041.10 which total was converted into shares of common stock of the Issuer. F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms. F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. |
| Unsecured Subordinated Convertible Promissory NoteSEC Table II · derivative / convertible security · Expires 2020-08-28 | Direct | 0 |
Reported balance
After 2019-11-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-07 · Conversion · Disposed Not disclosed · Balance 0 F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019. F8: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $2,034,191.85 which total was converted into shares of common stock of the Issuer. F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms. F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in connection with the Merger, upon the conversion of the outstanidng principal and any accrued and unpaid interest of two 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of August 14, 2019 and August 21, 2019, in the original principal amounts of $197,142.85 and $802,857.15, respectively.
F2: Dr. Moll's previously reported holdings of common stock of the Issuer of 929,809 shares was adjusted to reflect the Issuer's 1-for-15 reverse stock split that occurred on November 7, 2019, which resulted in Dr. Moll's ownership of 867,822 less shares of common stock.
F3: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 6,432,246 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.
F4: This Unsecured Subordinated Convertible Promissory Note was converted with a conversion price of $0.4664, which conversion occurred prior to the 1-for 15 reverse stock split that occurred on November 7, 2019.
F5: This Unsecured Subordinated Convertible Promissory Note was previously reported as covering 4,288,164 shares which conversion shares were adjusted to account for interest due thereon and reflect the 1-for-15 reverse stock split that occurred after the conversion on November 7, 2019.
F6: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $3,165,041.10 which total was converted into shares of common stock of the Issuer.
F7: This Unsecured Subordinated Convertible Promissory Note converted upon the consumation of the Merger, pursuant to its terms.
F8: Through the date of conversion, the principal and interest under this Unsecured Subordinated Convertible Promissory Note, totaled $2,034,191.85 which total was converted into shares of common stock of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 287,521 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-03-06 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-31 · Disposition to issuer · Disposed 17,381 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-31 · Disposition to issuer · Disposed 16,393 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2017 Filed May 10, 2017 16:09 UTC | BIOLASE, INC BIOL · Entity 11470 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-031221 · doc4.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: On May 6, 2016, the reporting person was granted 50,000 restricted stock units, which vested on May 6, 2017. F2 · derivative.expiration_date: On May 6, 2016, the reporting person was granted 50,000 restricted stock units, which vested on May 6, 2017. Read SEC document |
| May 08, 2017 Filed May 10, 2017 16:09 UTC | BIOLASE, INC BIOL · Entity 11470 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-031221 · doc4.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 19:33 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseWarrants (right to buy) · Derivative | 93,517 | $0.13 Strike: $1.80 | $11,689.63 |
DisclosureSEC source: 0001209191-17-027578 · doc4.xml · derivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,517 Underlying: Common Stock · 93,517 shares Expires 2022-04-18 F1 · security: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") and Warrants were acquired by Frederic H. Moll in a private placement with the Issuer that closed on April 18, 2017 (the "Closing"). Read SEC document |
| April 18, 2017 Filed Apr 19, 2017 19:33 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseSeries D Participating Convertible Preferred Stock · Derivative | 1,921 | $124.00 | $238,204.00 |
DisclosureSEC source: 0001209191-17-027578 · doc4.xml · derivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,921 Underlying: Common Stock · 192,100 shares Expires not disclosed F1 · security: These shares of Series D Participating Convertible Preferred Stock ("Preferred Stock") and Warrants were acquired by Frederic H. Moll in a private placement with the Issuer that closed on April 18, 2017 (the "Closing"). F2 · derivative.exercise_price: Each share of Preferred Stock will initially be convertible into 100 shares of Common Stock ("Shares"), reflecting a conversion price equal to $1.24 per Share. The conversion of the Preferred Stock will occur automatically upon the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), which is expected to occur after the Closing. The Preferred Stock has no expiration date. F2 · derivative.exercise_date: Each share of Preferred Stock will initially be convertible into 100 shares of Common Stock ("Shares"), reflecting a conversion price equal to $1.24 per Share. The conversion of the Preferred Stock will occur automatically upon the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), which is expected to occur after the Closing. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: Each share of Preferred Stock will initially be convertible into 100 shares of Common Stock ("Shares"), reflecting a conversion price equal to $1.24 per Share. The conversion of the Preferred Stock will occur automatically upon the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated April 11, 2017 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on April 14, 2017), which is expected to occur after the Closing. The Preferred Stock has no expiration date. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 19:36 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 7,570 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001562180-17-000295 · primarydocument.xml · derivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,570 Underlying: Common Stock · 7,570 shares Expires 2027-01-17 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2017. Read SEC document |
| September 10, 2003 Filed Sep 12, 2003 21:59 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 5,000 | $15.04 | $75,200.00 |
DisclosureSEC source: 0001209191-03-021411 · bpa93111_bpa1fhm.xml · nonDerivative · entry 2 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,799 Read SEC document |
| September 10, 2003 Filed Sep 12, 2003 21:59 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 5,000 | $15.06 | $75,300.00 |
DisclosureSEC source: 0001209191-03-021411 · bpa93111_bpa1fhm.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 662,799 Read SEC document |
| August 13, 2003 Filed Aug 16, 2003 00:54 UTC | INTUITIVE SURGICAL INC ISRG · Entity 2878 | SaleCommon Stock | 10,000 | $15.11 | $151,058.00 |
DisclosureSEC source: 0001209191-03-017415 · bpa92564_bpa1fhm.xml · nonDerivative · entry 1 MOLL FREDERIC H · CIK 0001260157 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 667,799 F1 · balance_after: Includes 289 shares acquired on July 31, 2003 pursuant to the Intuitive Surgical, Inc. employee stock purchase plan. F2 · balance_after: Reflects the 1-for-2 reverse stock split effected on July 1, 2003. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.